Compare RGP & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | BMEA |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 138.1M |
| IPO Year | 2000 | 2021 |
| Metric | RGP | BMEA |
|---|---|---|
| Price | $4.71 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $9.83 |
| AVG Volume (30 Days) | 313.6K | ★ 1.1M |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $551,331,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $0.87 |
| 52 Week High | $6.07 | $3.07 |
| Indicator | RGP | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 61.95 | 35.89 |
| Support Level | $4.21 | $1.05 |
| Resistance Level | $4.82 | $1.47 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 89.92 | 15.79 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.